Journal article
Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy
A Advani, KJ Wiggins, AJ Cox, Y Zhang, RE Gilbert, DJ Kelly
Nephrology | Published : 2011
Abstract
Aim: Early renal enlargement may predict the future development of nephropathy in patients with diabetes. The epidermal growth factor (EGF)-EGF receptor (EGFR) system plays a pivotal role in mediating renal hypertrophy, where it may act to regulate cell growth and proliferation and also to mediate the actions of angiotensin II through transactivation of the EGFR. In the present study we sought to investigate the effects of long-term inhibition of the EGFR tyrosine kinase in an experimental model of diabetes that is characterized by angiotensin II dependent hypertension. Methods: Female heterozygous streptozotocin-diabetic TGR(mRen-2)27 rats were treated with the EGFR inhibitor PKI 166 by dai..
View full abstractGrants
Funding Acknowledgements
The authors thank Mariana Pacheco, Sylwia Glowacka, Jemma Court and Suzanne Advani for their excellent technical assistance. Dr Andrew Advani is a Canadian Diabetes Association Clinician Scientist. Dr Richard E. Gilbert is a Canada Research Chair in Diabetes Complications. Dr Darren Kelly is an NHMRC Senior Fellow. This research was undertaken, in part, thanks to funding from the Canadian Diabetes Association, the CIHR and the Canada Research Chairs programme.A.A., R.E.G. and D.J.K. have received research funding and/or honoraria from Novartis Pharmaceuticals, the manufacturer of PKI 166, the compound used in this study.